/
CTXR
$0.74-$0.03 (-4.10%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$21.0M
27M shares
52-week range
$0.47 – $2.19
16% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-44.52
Citius Pharmaceuticals Inc. Common
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
www.citiuspharma.com- Employees
- 23
- IPO / List date
- Oct 18, 2011
- HQ
- CRANFORD, NJ
Held by traders on TradeandTell
No one on the platform currently holds CTXR.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CTXR as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-11-26 | 1-for-25reverse |
| 2017-06-09 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded CTXR yet.
